Impact of neoadjuvant chemotherapy on thrombus viability in patients with Wilms tumour and caval extension: systematic review with meta-analysis

**Authors**

Tristan D Boam, MBChB, MRCS (TB)

Department of Paediatric Surgery, Chelsea and Westminster Hospital, London, UK

Melissa Gabriel, MBBS (MG)

Department of Paediatric Surgery, Norfolk and Norwich Hospital, Norwich, UK

Rajeev Shukla MD, FRCPath (RS)

Department of Pathology, Alder Hey Children’s Hospital, Liverpool, UK

Paul D Losty MD,FRCSI FRCS (Ed) FRCS(Eng) FRCS (Paed) FEBPS (PDL)

Alder Hey Children’s Hospital NHS Foundation Trust, School of Health and Life Science, University of Liverpool, UK

**Corresponding authors**

Tristan D Boam, MBChB, MRCS (TB)

Department of Paediatric Surgery, Chelsea and Westminster Hospital, London, UK

Email: [Tristanboam@doctors.org.uk](mailto:Tristanboam@doctors.org.uk)

Tel: +447708 825 281

Paul D Losty MD, FRCSI FRCS (Ed) FRCS(Eng) FRCS (Paed) FEBPS

Alder Hey Children’s Hospital NHS Foundation Trust, School of Health and Life Science, University of Liverpool, UK

Email: [paul.losty@liverpool.ac.uk](mailto:paul.losty@liverpool.ac.uk)

Tel: +44 7803 047227

**Conflict of interest**

The authors declare no conflict of interests.

**Funding**

No specific funding declared

**Running head**

Wilms tumour IVC thrombus viability

**Keywords**

Wilms tumour, tumour thrombus, caval and atrial disease, cavectomy, cavotomy

Systematic review and Meta-analysis

**ABSTRACT**

Background

Inferior vena cava (IVC) tumour thrombus in children with Wilms tumour is typically managed with neoadjuvant chemotherapy with the intention of achieving thrombus regressionin order to minimise the risks associated with complex vascular surgery.

Methods

A systematic review of Medline and Embase databases was undertaken to identify all eligible studies with reference to thrombus viability in Wilms tumour index cases with caval / cardiac extension. A meta-analysis of proportions was utilised for pooled thrombus viability data across studies. Logistic regression analysed the relationship between thrombus viability and duration of chemotherapy.

Results

Thirty-five eligible observational studies and case reports met inclusion criteria describing a total of 236 patients with thrombus viability data. The pooled proportion of patients with viable tumour thrombus after neoadjuvant chemotherapy was 0.53 (0.43 - 0.63). Logistic regression analysis of 54 patients receiving either a standard (4-6 weeks) or extended (>6 weeks) course of neoadjuvant chemotherapy resulted in an Odds Ratio of 3.14 (0.97 – 10.16), p=0.056, with extended course therapy trending towards viable tumour thrombus.

Conclusion

Pre-operative chemotherapy is successful in achieving non-viability of caval and cardiac thrombi in around 50% of children, without added benefit from extended cycles of neoadjuvant chemotherapy. Risks versus benefits of extirpative vascular surgery must be considered therefore for these high-risk patients.

**INTRODUCTION**

Intra-vascular thrombus extension is a recognised hallmark of Wilms tumour, with extension into the inferior vena cava (IVC) in 4%-10% of cases1 and intra-cardiac lesions observed in 1- 3% cases.2–4 The thrombus in most cases is neoplastic, containing malignant cells disseminated from primary tumour growth. The Daum staging system classifies disease based on its level above or below the hepatic veins, intimal vessel involvement and whether there is right atrial or ventricular tumour extension, to aid surgeons in planning successful resection.3,5 Patients with supra-diaphragmatic extension often require cardio-pulmonary bypass (CPB) or deep hypothermic circulatory arrest to extract thrombi.1,3,4,6 For others, proximal and distal IVC occlusion alone may be sufficient.1,7–9 Both the National Wilms Tumour Study (NWTS) Group and The International Society of Paediatric Oncology (SIOP) protocols advocate preoperative chemotherapy to reduce perioperative complications and induce thrombus regression prior to radical nephrectomy to obviate the need for direct caval surgery or CPB.1,4,10,1112

Thrombectomy is undertaken for oncological control to achieve a complete resection, but may be required urgently to prevent complications from its haemodynamic effects, including tumour embolus, hepatic and cardiac failure.13–16

Mobile tumour thrombi are cleared by cavotomy and thrombectomy, but when thrombus is densely adherent to the vein wall, intimal dissection may be needed for total ‘piecemeal’ extraction.8,17,18 This risks caval narrowing and secondary thrombotic occlusion.1,6,17 Where thrombectomy is not feasible or the IVC is totally occluded by thrombus, partial or full cavectomy may be tolerated due to collateral venous flow.3,4,19–21 Caval repair can be undertaken by direct suturing or with bovine or autologous pericardial patches or synthetic grafts as necessary.4,15,20 Cavectomy carries significant added risk to the patient, relating to the increased complexity of the operation; potential inadequate collaterals with venous pooling in lower extremities, refractory ascites and direct hazards to the contralateral kidney.17 Some, but not all patients require caval reconstruction, depending on their haemodynamic response when the IVC is clamped at the supra-hepatic level, reflecting the adequacy of the collateral circulation.17 When the left kidney is left in situ, rich collaterals may develop from the gonadal, adrenal, ascending phrenic and lumbar veins as well as the azygos system.19,22 Where the right kidney is left behind, a reno-portal shunt may be required. Massive haemorrhage and death are well recognised, and likely under-reported, complications of caval and cardiac surgery.4,9,20

Wilms tumour patients with caval or cardiac extension (CCE) have comparable survival outcomes to those without vascular invasion and while results of the 3rd and 4th National Wilms Tumour Study (NWTS) showed the incidence of overall surgical complications to be decreasing, children with CCE are still categorised as a high risk group.1,23–25 It remains controversial whether removal of tumour thrombus is necessary in those patients where doing so would pose a significant risk to life. Pre-operative chemotherapy and adjuvant post-operative radiotherapy may conceivably be sufficient to achieve oncological control of malignant thrombus.

This study therefore investigated the effect of neoadjuvant chemotherapy on thrombus viability, in order to determine if complete thrombectomy is essential to achieve macro- and microscopically clear resection margins.

**METHODS**

*Systematic review*

A systematic review was undertaken in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines. Medline and Embase (Ovid®) databases were searched using the terms: Wilms, nephroblastoma, caval, vena cava, IVC, thrombus, intra-atrial, intracaval, intracardiac, intravascular, vascular, atrial, and atrium. Limits were set at human subjects, English language publications, patient ages 0-18 and studies from 1990 onwards. Searches were undertaken between April and May 2020. Title and/or abstract screening was undertaken independently by 2 study authors to identify original case reports, observational series and randomised trials including Wilms tumour with intravascular extension. Full texts were then retrieved and searched by a single author for references to paediatric Wilms tumour with intravascular extension beyond the renal vein, that received neoadjuvant chemotherapy, then nephrectomy and thrombectomy with subsequent full histological analysis of thrombus. Patients that did not receive neoadjuvant chemotherapy or that did not require thrombectomy were excluded. Eligible conference abstracts were also included. Where information about chemotherapy or thrombus histology was incomplete, authors of these studies were contacted directly by email. Tumour thrombi were classified as ‘viable’ if any active tumour cells were reported on histology examination. Reports of complete necrosis of the thrombus with no active tumour cells were classified as ‘non-viable’. Consensus agreement between all three study authors was used where data reporting was unclear. The most recent study was selected where there were multiple reports from the same institution. Reference lists of all included studies were manually searched.

*Statistical analysis*

StatsDirect software was used.26 A meta-analysis of proportions analysed pooled thrombus viability data across studies and a random effects model were applied. Logistic regression was used to analyse the relationship between thrombus viability and length of chemotherapy, using data from individual patients where complete and amenable to comparison. Patients were then categorised by the duration of neoadjuvant chemotherapy as (i) short course < 4 weeks; (ii) standard course 4-6 weeks or (iii) extended course >6 weeks.27 Where the length of neoadjuvant chemotherapy was reported in terms of cycles, courses, doses or protocols; standardised Wilms tumour regimens for the same agents were used to convert these terms to weeks, for adequate comparisons to be made.

**RESULTS**

*Systematic review*

The initial search strategy yielded 734 studies after removal of duplicates. [(Figure 1)](file:///C:\Users\Derek\AppData\Local\Microsoft\Windows\INetCache\IE\5PV50SS2\Wilms%20Figure%201%20-%20PRISMA%202009%20flow%20diagram.doc) After title and abstract screening, 177 articles were retrieved, 36 of which were conference abstracts with 13 studies identified through manual bibliography searching. Sixty-seven authors were also directly contacted with 30 further responses. Twelve articles were unavailable. This resulted in the identification of a total 35 eligible studies, including 5 conference abstracts that met final inclusion criteria. Of these, 20 studies required direct correspondence with study authors to verify update information.[(Table 1)](file:///C:\Users\Derek\AppData\Local\Microsoft\Windows\INetCache\IE\5PV50SS2\Table%201%20Studies.docx) All included studies on the theme topic were observational, the majority were case reports or small case series, with only 4 study series involving more than 20 patients. There were no prospective trials comparing interventions for CCE in Wilms tumour.

Thrombus viability data were available for a total of 236 patients with CCE. All patients received pre-operative chemotherapy, mostly in line with SIOP and NWTS regimens involving actinomycin D (ActD) and vincristine (VCR) +/- doxorubicin.

Eight studies with a total of 86 patients described alternative agents and in two studies pre-operative radiotherapy was administered to a total of 6 patients. In 2 studies it was not possible to fully separate histology results where the thrombus had regressed to the renal vein, and therefore did not require extensive caval thrombectomy.28,29 One study report included 2 patients with non-Wilms histology,15 and another publication described the use of Trans-Arterial Chemoembolisation (TACE) on the primary tumour, in addition to systemic neoadjuvant chemotherapy.30 These studies were excluded from the sensitivity analysis.

*Meta-analysis*

After qualitative synthesis, it was deemed that the studies were similar enough (I2=46%, moderate heterogeneity) with regards to the outcome of thrombus viability to pool patient data in a meta-analysis. The pooled proportion of patients with viable tumour thrombus after neoadjuvant chemotherapy was 0.53 (0.43 - 0.63). [(Figure 2)](file:///C:\Users\Derek\AppData\Local\Microsoft\Windows\INetCache\IE\5PV50SS2\Figure%202%20Forest%20plot.docx) A sensitivity analysis, that excluded the 5 studies that included patients that had neoadjuvant radiotherapy, renal vein thrombi and non-Wilms tumours yielded similar results to the original analysis, with a proportion of viable tumour thrombus of 0.49 (0.36 – 0.61). [(Table S1, Supporting information)](file:///C:\Users\Derek\AppData\Local\Microsoft\Windows\INetCache\IE\5PV50SS2\Appendix%201%20sensitivity%20analysis.docx) In the absence of moderate sized studies, Funnel Plots indicated significant heterogeneity and asymmetry, suggesting risk of bias. [(Figure S1, Supporting information)](file:///C:\Users\Derek\AppData\Local\Microsoft\Windows\INetCache\IE\5PV50SS2\Appendix%202%20Funnel%20plot.docx)

A total of 54 patients from 21 studies were included in the logistic regression, having had either standard or extended courses of chemotherapy. Short course neoadjuvant chemotherapy was described in only 2 patients, both of whom had viable tumour thrombus, so these were therefore excluded. In total, 36 patients received a standard chemotherapy course. Of these 12 had viable tumour thrombus. The remaining 18 patients received an extended course of chemotherapy with 11 cases having viable tumour thrombus. Logistic regression resulted in an Odds Ratio of 3.14 (0.97 – 10.16), p=0.056, trending towards extended courses of chemotherapy having viable tumour thrombus. (Table 2)

**DISCUSSION**

This study has provided a comprehensive systematic review of thrombus viability after chemotherapy for Wilms tumour using PRISMA methodology. Limitations are acknowledged, reflecting the available literature on this topic. It is highly likely that that the positive outcomes reported by some authors are indicative of publication bias. There are no prospective studies or randomised controlled trials specifically focused on surgical or other interventions in management of CCE in Wilms tumour.

The present systematic review did not include a formal assessment of study quality, as there are few validated tools available for the evaluation of case series and case reports and the outcome of interest was specific and not related to overall quality of a study. In addition, a significant number of results were obtained by directly contacting study authors, allowing for an in-depth appraisal of the available literature on this rare condition.

Several common themes were identified related to reporting Wilms tumour with CCE. In several series, the focus was on the thrombus, with the management and outcomes of several types of tumour being described; making it difficult to extrapolate wholly accurate data. Neoadjuvant chemotherapy protocols were often specified but lacked details that might have indicated deviation from regulatory practice. Interpretation of these studies was therefore reliant on direct author contact and comparisons with the standardised regimens. Most studies did not accurately detail radiological or macroscopic tumour response to chemotherapy prior to surgery. It was also not possible to fully define how neoadjuvant radiotherapy influenced thrombus viability or separate these patients from the series where they were reported, which made exclusion of these studies from the sensitivity analysis necessary. Resection margins were not often discussed, and it remains unclear whether incomplete thrombectomy increases the risk of disease relapse.1,2,14,15,24,31,32 Adjuvant radiotherapy was usually given in these situations as mandated by tumour staging protocols, but post-operative chemotherapy, relapse and mortality outcomes were often generalised, and it was difficult to fully define relationships between these and thrombus response and viability. Future studies would benefit from a standardised reporting structure for Wilms tumour patients harbouring CCE, to address these issues and allow greater clarity and comparability of outcomes. This should include a standard system for macroscopic / radiological thrombus response reporting using an existing staging system such as those described by Daum or Hinman.5,17

Meta-analysis was considered appropriate as there was sufficient similarity between the included studies with a binary outcome of interest – whether there was tumour thrombus viability or non-viability.Despite moderate heterogeneity between the included studies, the results of the sensitivity analysis, which excluded studies that described radiotherapy, renal vein thrombi and non-Wilms histology, were similar to that of the main analysis.

A previous meta-analysis found no survival benefits to extended courses of chemotherapy in Wilms patients with intra-vascular extension, confirmed by the present study.27 These longer courses of chemotherapy may reflect the lack of radiological regression of thrombus, indicating the absence of macro- or microscopic response, although a single study reported no association between macroscopic appearances and microscopic response.25 In the present study, no assumptions were made about the comparability of patients given standard or extended courses of chemotherapy. Of the 8 studies detailing patients with extended courses, there was no explanation given for the length of treatment, and there were no obvious clinical descriptors to differentiate them from patients that were given standard courses.

The present systematic review raises several key questions and challenges that would be usefully addressed by future prospective studies. Potential areas for investigation include prediction of thrombus viability from novel imaging or biomarkers, efficacy of novel agents for thrombus regression and surgery-led trials comparing clinical outcome metrics with respect to thrombus extraction versus chemotherapy and adjuvant targeted radiotherapy.

This systematic review with meta-analysis has confirmed that neoadjuvant chemotherapy was effective in achieving thrombus non-viability in around 50% of patients with tumour extension into the vena cava. This raises the key issue as to whether complex vascular surgery should be considered mandatory for all such patients. While it is impossible with current imaging technology to determine whether a thrombus is biologically viable or not before surgery, if this could be determined more accurately with innovative tools then the extent of surgery might well be modified in future.

**ACKNOWLEDGMENTS**

Special thanks are owed to Catrin Tudur, Statistician, University of Liverpool, UK; Surgical Residents Seo-Hwa Chung and David Fawkner-Corbett MRCS

**REFERENCES**

1 Szavay P, Luithle T, Semler O, Graf N, Fuchs J. Surgery of cavoatrial tumor thrombus in nephroblastoma: a report of the SIOP/GPOH study. *Pediatr Blood Cancer*. 2004 Jul; **43**: 40–45.

2 Akyuz C, Emir S, Buyukpamukcu N, Atahan L, Caglar M, Kutluk T, *et al.* Cavoatrial tumor extension in children with wilms tumor: a retrospective review of 17 children in a single center. *J Pediatr Hematol Oncol*. 2005 May; **27**: 267–269.

3 Abdullah Y, Karpelowsky J, Davidson A, Thomas J, Brooks A, Hewitson J, *et al.* Management of nine cases of Wilms’ tumour with intracardiac extension - a single centre experience. *J Pediatr Surg*. 2013 Feb; **48**: 394–399.

4 Cox SG, Davidson · A, Thomas · J, Brooks · A, Hewitson · J, Numanoglu · A, *et al.* Surgical management and outcomes of 12 cases of Wilms tumour with intracardiac extension from a single centre. *Pediatr Surg Int*. 2018; **34**: 227–235.

5 Daum R, Roth H, Zachariou Z. Tumor infiltration of the vena cava in nephroblastoma. *Eur J Pediatr Surg Off J Austrian Assoc Pediatr Surg .[et al] = Zeitschrift fur Kinderchirurgie*. 1994 Feb; **4**: 16–20.

6 Aspiazu D, Fernandez-Pineda I, Cabello R, Ramirez G, Alvarez-Madrid A, Agustin JC De. Surgical management of Wilms tumor with intravascular extension: a single-institution experience. *Pediatr Hematol Oncol*. 2012 Feb; **29**: 50–54.

7 Lodge AJ, Jaggers J, Adams D, Rice HE. Vascular control for resection of suprahepatic intracaval Wilms’ tumor: technical considerations. *J Pediatr Surg*. W.B. Saunders; 2000 Dec; **35**: 1836–1837.

8 Bader MI, Abdelaal K, Rogers T, Arul SG. A surgical approach to Wilms’ tumour with retrohepatic vena caval extension. *Pediatr Surg Int*. 2013 Mar; **29**: 229–232.

9 Schettini ST, Da Fonesca JHAP, Abib SCV, Telles CA, Xerfan Haber M, Rizzo MFV, *et al.* Management of Wilms’ tumor with intracardiac extension. *Pediatr Surg Int*. Springer Verlag; 2000; **16**: 529–532.

10 Mushtaq I, Carachi R, Roy G, Azmy A. Childhood renal tumours with intravascular extension. *Br J Urol*. 1996 Nov; **78**: 772–776.

11 Ritchey ML, Kelalis PP, Haase GM, Shochat SJ, Green DM, D’Angio G. Preoperative therapy for intracaval and atrial extension of Wilms tumor. *Cancer*. 1993 Jun; **71**: 4104–4110.

12 Al Diab A, Hirmas N, Almousa A, Abu-hijlih R, Aljlouni F, Sultan I, *et al.* Inferior vena cava involvement in children with Wilms tumor. *Pediatr Surg Int*. 2017;

13 Viswanathan A, Kumar N, Mathew AK, Narendra Babu M, Subramanian AP, Appaji L. Wilms tumor with extensive cardiac thrombus: a multidisciplinary approach. *Asian Cardiovasc Thorac Ann*. SAGE Publications Inc.; 2020 Feb 1; **28**: 101–103.

14 Imle R, Tosev G, Behnisch W, Schenk JP, Rauch H, Mueller A, *et al.* Intracardiac Extension of Wilms Tumor: A Case of a 2.5-Year-Old Girl Presenting with Upper Venous Congestion Caused by Tumor Growth into the Right Cardiac Ventricle. *Case Rep Oncol*. S. Karger AG; 2019 Jan 1; **12**: 33–38.

15 Murthi G V, Kocyildirim E, Sellathury S, Cuckow PM, Wilcox DT, Michalski A, *et al.* Wilms’ tumour with persistent intravascular extension: a review of the surgical aspects of management. *J Pediatr Urol*. 2006 Oct; **2**: 439–445.

16 Genc DB, Vural S, Telhan L, Yukcu B, Oner T. Wilms Tumor Presenting With Fulminant Hepatic Failure and Successful Initial Treatment With Cyclophosphamide. Pediatr. Blood Cancer. John Wiley and Sons Inc.; 2016. p. 177–178.

17 Loh A, Bishop M, Krasin M, Davidoff AM, Jr MRL. Long-term physiologic and oncologic outcomes of inferior vena cava thrombosis in pediatric malignant abdominal tumors. *J Pediatr Surg*. 2015 Apr; **50**: 550–555.

18 Kieran K, Ehrlich PF. Current surgical standards of care in Wilms tumor. *Urol Oncol*. 2016 Jan; **34**: 13–23.

19 Ribeiro RC, Schettini ST, Sde CA, da Fonseca JH, Cypriano M, da Silva NS. Cavectomy for the treatment of Wilms tumor with vascular extension. *J Urol*. 2006 Jul; **176**: 274–279.

20 Lall A, Pritchard-Jones K, Walker J, Hutton C, Stevens S, Azmy A, *et al.* Wilms’ tumor with intracaval thrombus in the UK Children’s Cancer Study Group UKW3 trial. *J Pediatr Surg*. 2006 Feb; **41**: 382–387.

21 McMahon S, Carachi R. Wilms’ tumor with intravascular extension: A review article. *J Indian Assoc Pediatr Surg*. 2014 Oct; **19**: 195–200.

22 Trobs RB. Anatomical basis for Wilms tumor surgery. *J Indian Assoc Pediatr Surg*. 2009 Apr; **14**: 50–54.

23 Ritchey ML, Shamberger RC, Haase G, Horwitz J, Bergemann T, Breslow NE. Surgical complications after primary nephrectomy for Wilms’ tumor: report from the National Wilms’ Tumor Study Group. *J Am Coll Surg*. 2001 Jan; **192**: 63–68; quiz 146.

24 Shamberger RC, Ritchey ML, Haase GM, Bergemann TL, Loechelt-Yoshioka T, Breslow NE, *et al.* Intravascular extension of Wilms tumor. *Ann Surg*. 2001 Jul; **234**: 116–121.

25 Elayadi M, Hammad M, Sallam K, Ahmed G, Ahmed S, Ibrahim A, *et al.* Management and outcome of pediatric Wilms tumor with malignant inferior Vena cava thrombus: largest cohort of single-center experience. *Int J Clin Oncol*. Springer; 2020 Apr 5; 1–7.

26 England: StatsDirect Ltd. StatsDirect statistical software. 2013.

27 Morris L, Squire R, Sznajder B, van Tinteren H, Godzinski J, Powis M. Optimal neoadjuvant chemotherapy duration in Wilms tumour with intravascular thrombus: A literature review and evidence from SIOP WT 2001 trial. *Pediatr Blood Cancer*. John Wiley and Sons Inc.; 2019 Nov 1; **66**: e27930.

28 Bhagat M, Qureshi S, Kembhavi S, Vora T, Ramadwar M, Chinnaswamy G. Outcomes of surgery for renal tumours with intravascular extension. *Pediatr Blood Cancer*. M. Bhagat, Tata Memorial Hospital, Paediatric Surgery Oncology, Mumbai, India: John Wiley and Sons Inc.; 2016; **63**: S44–S45.

29 Cristofani LM, Duarte RJ, Almeida MT, Filho VO, Maksoud JG, Srougi M. Intracaval and intracardiac extension of Wilms’ tumor. The influence of preoperative chemotherapy on surgical morbidity. *Int Braz J Urol*. 2007; **33**: 683–689; discussion 689.

30 Li M, Xu S, Huang Y, Shu Q, Wang J, Lai C. Multimodality therapy for wilms’tumor with inferior vena cava and atrial tumor thrombus. *Pediatr Blood Cancer*. M. Li, Department of Pediatric Surgery, Children’s Hospital, Zhejiang University, Hangzhou, China: John Wiley and Sons Inc.; 2014; **61**: S407.

31 Xu S, Sun N, Zhang WP, Song HC, Huang CR. Management of Wilms tumor with intravenous thrombus in children: a single center experience. *World J Pediatr*. Institute of Pediatrics of Zhejiang University; 2019 Oct 1; **15**: 476–482.

32 Szymik-Kantorowicz S, Urbanowicz W, Malec E, Kordon Z. Right atrial extension of Wilms’ tumor. *Med Sci Monit*. 2003 Mar 1; **9**.

33 Altwaeel H, Kabbani MS, Al Shammari A, Al-Namshan M, Alghamdi AA. Perioperative management of Wilms’ tumor with intracardiac extension: Report of two cases with review of literature. *J Saudi Hear Assoc*. Elsevier B.V.; 2019 Nov 14;

34 Tekin A, Yağmur İ, Ergün O, Ayık MF, Atay Y, Ulman İ, *et al.* Excision of the atrial wilms’ tumor thrombus without sternotomy, atriotomy and cardiovascular by-pass. *Turk J Pediatr*. Turkish Journal of Pediatrics; 2019; **61**: 436–439.

35 John R, Kurian JJ, Sen S, Gupta MK, Jehangir S, Mathew LG, *et al.* Clinical outcomes of children with Wilms tumor treated on a SIOP WT 2001 protocol in a tertiary care hospital in south India. *J Pediatr Urol*. 2018;

36 Sekhon V, Suryavanshi M. Nephroureterectomy with inferior vena-caval thrombectomy in post-chemotherapy Wilms’ tumour in a child – From the eyes of the surgeon! *J Pediatr Urol*. Elsevier Ltd; 2018 Aug 1; **14**: 351–352.

37 Tan XH, Zhang DY, Liu X, Lin T, He DW, Li XL, *et al.* Retrospective analysis to determine outcomes of patients with bilateral Wilms tumor undergoing nephron sparing surgery: 15-year tertiary single-institution experience. *Pediatr Surg Int*. Springer Verlag; 2018 Apr 1; **34**: 427–433.

38 Dong K, Weijin H, Xianmin X, Kai L. Treatment of nephroblastoma with venous thrombus: Single-center experience. *Pediatr Blood Cancer*. K. Dong, Children’s Hospital of Fudan University, Surgery, Shanghai, China: John Wiley and Sons Inc.; 2018; **65**: S471.

39 Solomon Z, Loveland J, Candy G, Poole J, Wainwright L. Bilateral wilms tumour: A ten year experience in two academic centers. *Pediatr Blood Cancer*. Z. Solomon, University of the Witwatersrand, Chris Hani Baragwanath Academic Hospital, Paediatric Surgery, Johannesburg, South Africa: John Wiley and Sons Inc.; 2016; **63**: S249.

40 Fawkner-Corbett DW, Howell L, Pizer BL, Dominici C, McDowell HP, Losty PD. Wilms’ tumor--lessons and outcomes--a 25-year single center UK experience. *Pediatr Hematol Oncol*. 2014 Aug; **31**: 400–408.

41 Lee YT, Jacobsen AS, Chui CH. Management of wilms tumour with inferior vena cava extension: A single-institution experience. *Pediatr Blood Cancer*. Y.T. Lee, Paediatric Surgery, KK Women’s and Children’s Hospital, Singapore, Singapore: John Wiley and Sons Inc.; 2014; **61**: S406.

42 Parelkar S V, Mundada D, Oak SN, Sanghvi B V, Joshi PB, Kapadnis SP, *et al.* Nonresponsiveness to chemotherapy: a formidable surgical challenge in wilms’ tumor with intracardiac extension. *Indian J Surg Oncol*. 2013 Dec; **4**: 362–365.

43 Khozeimeh N, Sinha P, Dome JS, Jr PCG. Strategy for management of retroperitoneal tumors with caval tumor thrombus. *J Pediatr Surg*. 2011 Nov; **46**: 2065–2070.

44 Hadley GP, Sheik-Gafoor MH, Buckels NJ. The management of nephroblastoma with cavo-atrial disease at presentation: experience from a developing country. *Pediatr Surg Int*. 2010 Dec; **26**: 1169–1172.

45 Renaud EJ, Liu D, Pipe SW, Rubin MA, Teitelbaum DH. Inferior vena cavectomy for nonexcisable Wilms’ tumor thrombus. *J Pediatr Surg*. 2001 Mar; **36**: 526–529.

46 Gow KW, Dome JS, Iglesias J, Novick WM, Hoffer FA, Davidoff AM. Intraatrial and intracaval Wilms’ tumor. *J Pediatr Surg*. W.B. Saunders; 2001 Dec; **36**: 1869–1871.

47 Giannoulia-Karadana A, Moschovi M, Koutsovitis P, Tolis G, Tzortzatou-Stathopoulou F. Inferior vena cava and right atrial thrombosis in children with nephroblastoma: Diagnostic and therapeutic problems. *J Pediatr Surg*. W.B. Saunders; 2000 Oct; **35**: 1459–1461.

48 Sripathi V, Muralidharan K V., Ramesh S, Muralinath S. Wilms’ tumor with vena caval, atrial, and middle hepatic vein tumor thrombus. *Pediatr Surg Int*. 2000 Jul; **16**: 447–448.

49 Matloub YH, D’Angio GJ, Le Gras MD, Rosenberg HC, Dar AR, Girvan D, *et al.* Massive intra-atrial Wilms’ tumor: A treatment dilemma. *Med Pediatr Oncol*. 1997. p. 149–153.

50 Martínez-Ibáñez V, Sánchez de Toledo J, De Diego M, Castellote A, Sábado C, Javier G, *et al.* Wilms’ tumours with intracaval involvement. *Med Pediatr Oncol*. 1996 Apr; **26**: 268–271.

51 Habib F, McLorie GA, McKenna PH, Khoury AE, Churchill BM, Borden TA. Effectiveness of preoperative chemotherapy in the treatment of Wilms tumor with vena caval and intracardiac extension. *J Urol*. 1993; **150**: 933–935.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Table 1: List of all studies | | | | | | |
| Study | **Date** | **Number of patients receiving pre-operative chemotherapy** | **Number with viable tumour thrombus on resection** | **Length of chemotherapy (Weeks)** | **Chemotherapy regimen** | **Notes** |
| Elayadi 25 | 2020 | 31 | 20 | 6-12 | VCR/ActD/Doxorubicin |  |
| Viswanathan 13 | 2019 | 1 | 1 | 1 | VCR/ActD |  |
| Altwaeel\* 33 | 2019 | 2 | 2 | Not specified | Not specified |  |
| Imle\* 14 | 2019 | 1 | 0 | 4 | VCR/ActD |  |
| Tekin\* 34 | 2019 | 1 | 0 | 6 | Ifosfamide/Carboplatin/Etoposide |  |
| John\* 35 | 2018 | 1 | 0 | 6 | VCR/ActD/Doxorubicin |  |
| Sekhon\* 36 | 2018 | 1 | 0 | 6 | VCR/ActD |  |
| Tan\* 37 | 2018 | 2 | 0 | Not specified | VCR/ActD/Doxorubicin |  |
| Dong\*† 38 | 2018 | 7 | 0 | 4-7 | Ifosfamide/Etoposide/VCR/ActD/Doxorubicin |  |
| Cox\* 4 | 2018 | 11 | 9 | 5 (Median) | VCR/ActD/Doxorubicin |  |
| Al Diab 12 | 2017 | 10 | 8 | 7 (Median) | VCR/ActD/Doxorubicin |  |
| Solomon\*† 39 | 2016 | 9 | 4 | Not specified | Not specified |  |
| Bhagat † 28 | 2016 | 20 | 13 | Not specified | 3 drug not specified | Includes 2 patients with renal vein thrombi after chemotherapy |
| Genc\* 16 | 2015 | 1 | 1 | 6 | VCR/ActD/Cyclophosphamide |  |
| Fawkner-Corbett\* 40 | 2014 | 6 | 4 | 6-16 | VCR/ActD +/- Doxorubicin |  |
| Li\*† 30 | 2014 | 1 | 0 | 9 + TACE\* | Ifosfamide/Carboplatin/Etoposide/Pirarubicin/Vindesine | Also received Trans-Arterial Chemoembolisation |
| Lee † 41 | 2014 | 3 | 0 | 4-9 | VCR/ActD/Doxorubicin |  |
| Loh 17 | 2014 | 10 | 5 | Not specified | Not specified |  |
| Parelkar 42 | 2013 | 1 | 1 | 8 | VCR/ActD/Doxorubicin |  |
| Bader 8 | 2013 | 9 | 6 | 4-6 | VCR/ActD/Doxorubicin |  |
| Khozeimeh 43 | 2011 | 2 | 2 | 6, 10 | VCR/ActD/Doxorubicin |  |
| Hadley 44 | 2010 | 31 | 24 | 4 (+/- 6 Epirubicin) | VCR/ActD (+/- Epirubicin) |  |
| Cristofani 29 | 2007 | 9 | 6 | 4-6 | VCR/ActD | Includes 2 patients with renal vein thrombi after chemotherapy |
| Murthi 15 | 2006 | 11 | 8 | 1-29 (10 Mean) | VCR/ActD/Doxorubicin | Includes 1 PNET and 1 Clear cell sarcoma |
| Akyuz 2 | 2005 | 2 | 0 | 4 | VCR/ActD |  |
| Szymik-Kantorowicz 32 | 2003 | 1 | 0 | 6 | VCR/ActD/Epirubicin |  |
| Renaud 45 | 2001 | 1 | 1 | 10 | VCR/ActD/Doxorubicin | Patient received neoadjuvant radiotherapy |
| Gow 46 | 2001 | 1 | 1 | Not specified | VCR/ActD/Doxorubicin |  |
| Shamberger 24 | 2001 | 42 | 22 | 8 (Median) | VCR/ActD (+/- Doxorubicin +/-Cyclophosphamide) | 5 patients received neoadjuvant radiotherapy |
| Giannoulia-Karadana\* 47 | 2000 | 1 | 1 | 6 | VCR/ActD/Cyclophosphamide |  |
| Lodge 7 | 2000 | 1 | 0 | 12 | VCR/ActD/Doxorubicin |  |
| Sripathi 48 | 2000 | 1 | 1 | 6 | VCR/ActD/Doxorubicin |  |
| Matloub 49 | 1997 | 1 | 0 | 11 | VCR/ActD |  |
| Martìnez-Ibàñez 50 | 1996 | 1 | 0 | 6 | VCR/ActD/Epirubicin | Intra-operative biopsy from caval thrombus only |
| Habib 51 | 1993 | 3 | 0 | 6 | VCR/ActD |  |

\*Study required additional unpublished information from authors before inclusion

†Conference abstract